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Abstract
Background: Paranoia is one of the most common symptoms of schizophrenia-spectrum disorders, and is
associated with significant distress and disruption to the person’s life. Developing more effective and
accessible psychological interventions for paranoia is a clinical priority. Our research team has approached
this challenge in two main ways: firstly, by adopting an interventionist causal approach to increase effectiveness and
secondly, by incorporating user-centred inclusive design methods to enhance accessibility and usability. Our resultant
new digital intervention, SlowMo, intensively targets a reasoning style associated with paranoia, fast thinking,
characterised by jumping to conclusions and belief inflexibility. It consists of an easy-to-use, enjoyable and
memorable digital interface. An interactive web-based app facilitates delivery of face-to-face meetings which
is then synchronised with an innovative mobile app for use in daily life.
Methods/Design: We aim to test the clinical efficacy of SlowMo over 24 weeks to determine the mechanisms through
which it reduces paranoia, and to identify participant characteristics that moderate its effectiveness. In a parallel-group
randomised controlled trial, with 1:1 allocation, 360 participants with distressing persecutory beliefs will be independently
randomised to receive either the SlowMo intervention added to treatment as usual (TAU) or TAU, using randomly varying
permuted blocks, stratified by paranoia severity and site. Research workers will be blind to therapy allocation. The primary
outcome is paranoia severity over 24 weeks; our hypothesised mechanism of change is reasoning; moderators include
negative symptoms and working memory; and secondary outcomes include wellbeing, quality of life, and service use. The
accessibility, usability and acceptability of the digital platform will be assessed.
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Discussion: SlowMo has been developed as the first blended digital therapy to target fears of harm from others through
an inclusive design approach. In addition to testing its efficacy, this trial will add to our understanding of
psychological mechanisms in paranoia. The study will examine the usability and adherence of a novel digital
therapy, including an app for self-management, in a large sample of people affected by severe mental health
difficulties.
Trial registration: ISRCTN registry, ID: ISRCTN32448671. Registered prospectively on 30 January 2017. Date
assigned 2 February 2017.
Keywords: Delusions, Persecutory, Fast and slow thinking, Belief flexibility, Jumping to conclusions, mHealth,
eHealth, Digital therapy, User-centred design
Background
People often experience distressing fears about other
people intentionally causing them harm: this is known as
paranoia [1]. The severity of paranoia lies on a continuum,
ranging from fleeting ideas that someone on the street
might be laughing at us, to more elaborate and persistent
beliefs (sometimes called persecutory delusions) such as
that the secret services are trying to have us killed. Para-
noia is one of the most common symptoms of
schizophrenia-spectrum disorders, and is associated with
significant distress and disruption to the person’s life [2].
This results in increased use of services, including in-
patient admissions, and high costs to mental health care
providers. Developing effective interventions for paranoia
is, therefore, a clinical priority. The National Institute for
Health and Care Excellence (NICE; 2014) recommends
cognitive-behavioural therapy for psychosis (CBTp), in-
cluding paranoia [3]. However, there are significant chal-
lenges to access, engagement, adherence and effectiveness
[4–6]. CBTp has relatively high training and delivery costs,
which limits availability. Even when it is offered, people
may be reluctant to engage in therapy, and can struggle to
remember what is discussed or apply new learning to daily
life. Recent meta-analytical studies of CBTp have found
small- to medium-sized beneficial effects on paranoia, and
a pressing need to improve outcomes has been identified
[6]. Our research team has approached this challenge in
two main ways: firstly by adopting an interventionist
causal approach [7] to increase CBTp effectiveness and
secondly by incorporating user-centred inclusive design
methods to enhance accessibility and usability. Our result-
ant new digital intervention, SlowMo, aims to improve the
appeal, ease of use, memorability and clinical effectiveness
of psychological therapy for people who fear harm from
others.
The interventionist causal approach to improving ther-
apy effectiveness involves first identifying mechanisms
that play a causal role in paranoia (e.g. reasoning, worry,
negative self-beliefs, safety behaviours and sleep dysfunc-
tion) and then developing tailored interventions to target
these causal processes [8, 9]. These targeted interventions
are anticipated to reduce paranoia severity through differ-
ent pathways given the multifactorial causality of paranoia.
For example, a recent randomised controlled trial of a
brief intervention focussed on worry processes demon-
strated that reductions in this mechanism accounted for
improvements in paranoia [10]. In contrast, SlowMo
works by intensively targeting a certain type of thinking
associated with paranoia, which can be thought of as fast
thinking [11–13]. Fast thinking is characterised by focus-
sing on too little information (‘jumping to conclusions’)
and belief inflexibility (high conviction in thoughts and a
lack of consideration of alternative ideas [13]). It has been
robustly linked to paranoia [8, 12–17]. Systematic at-
tempts to modify this style of reasoning include group-
based, metacognitive training (MCT) and, more recently,
individual training (MCT+) developed by Moritz and col-
leagues [18]. Whilst earlier findings for MCT were prom-
ising, more robust designs have not shown consistent
improvements in reasoning, or paranoia at long-term
follow-up, particularly for those with more severe difficul-
ties [19–21].
The SlowMo intervention builds on the important
work of Moritz and colleagues and is the endpoint of a
decade of development and testing in four studies target-
ing fast thinking in paranoia [12, 22–24]. The first ver-
sions of the intervention were tested iteratively, in three
randomised studies and one case series, with develop-
ments over time in intervention content, duration and
name, whilst always targeting aspects of fast thinking
and paranoia [12, 22–24]. We found reductions in un-
helpful fast thinking and improvements in paranoia se-
verity. In an experimental study [12] designed to
examine mediation, we found preliminary evidence that
changes in belief flexibility mediated improvements in
paranoia. Most recently, in a feasibility randomised con-
trolled trial, 31 participants with paranoia were recruited
and randomly allocated 2:1 to the Thinking Well inter-
vention or treatment as usual (TAU) [24]. The interven-
tion involved face-to-face sessions with a therapist,
initially working on a brief computer-based programme
targeting reasoning biases [23] followed by four additional
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therapy sessions (with no additional digital component)
aimed at generalising the learning to real-world situations.
We found reductions in fast thinking (belief flexibility and
jumping to conclusions) and promisingly large effects (ef-
fect size d = 1.1) on paranoia severity. However, assess-
ments were not blinded and the sample size was small.
Further, whilst the acceptability of the intervention was
high, participants suggested ways in which the interven-
tion could be made more personalised, enjoyable and ap-
plicable to daily life. Our experimental work also indicated
that people with more working memory difficulties and
negative symptoms benefitted less from the therapy. This
current iteration (SlowMo) shares the focus on reasoning
of its predecessors (Maudsley Review Training
Programme [23] and Thinking Well [24]). However, whilst
previous versions of the intervention relied on verbal pres-
entation of material using PowerPoint and pen-and-paper
tools, SlowMo uses a website and app for interactive,
multimodal communication of information, together with
consistent use of normalising (everyday) language.
Incorporating digital technologies into psychological
interventions presents unique opportunities for improv-
ing outcomes, understanding mechanisms of change and
reducing costs [25–27]. However, to deliver meaningful
change in health care, digital solutions need to be tai-
lored to meet the specific needs of their users and to be
trustworthy with regard to safety, privacy and effective-
ness [28–31]. To meet this challenge, the development
of SlowMo therapy has involved a user-centred inclusive
design approach. Inclusive design aims to address the
needs of the broadest range of users possible, a crucial
issue given the heterogeneity of psychosis. Our design
approach was informed by the Design Council’s double
diamond method [32], which comprises the following
phases: discover, define, develop and deliver. Import-
antly, stakeholders (service users, clinicians, researchers,
technologists, innovation design engineers), including
sampling of ‘extreme’ users [33], were involved from the
outset, with iterative exploration, prototype testing and
feedback informing the design and development of
SlowMo.
SlowMo aims to assist people with paranoia by sup-
porting them to notice their upsetting concerns and
fast-thinking habits, and then providing them with strat-
egies to slow down for a moment in order to focus on
new information and develop safer thoughts [34]. It con-
sists of an easy-to-use, enjoyable and memorable digital
interface. Thoughts are visualised as bubbles, with differ-
ent speeds, sizes and colours reflecting different thinking
habits, intensities of emotion and coping tips. This sim-
ple visual metaphor aims to help people to understand
that thoughts are transient, and that we can modify
them by using coping strategies. Based on session con-
tent from earlier work, an interactive web-based app
facilitates the delivery of face-to-face meetings. This is
then synchronised with an innovative, mobile app for
use in daily life, which is ‘native’ (i.e. one that runs on
the phone and can work offline). Feasibility testing of an
early prototype has been conducted with acceptability,
usability and enjoyment assessed through a self-report
10-item User Experience Survey, adapted from use in a
previous study examining the feasibility of a mobile app
for the management of psychosis [35]. The measure gen-
erates a mean percentage for each dimension of user ex-
perience, ranging from 0 (totally disagree) to 100 (totally
agree). Results were extremely positive, with high rates
of acceptability, usability and enjoyment (>75%). Partici-
pants indicated that they significantly preferred the
digital interface to conventional therapy materials. This
is particularly encouraging in the context of digital inter-
ventions given recent evidence that overall uptake of a
therapeutic app for psychosis delivered in a naturalistic
setting was low [30]. Given these data on the digital
interface, together with the proof-of-concept, feasibility
and acceptability evidence from our four preliminary
studies [12, 22–24], we are now well placed to test the
SlowMo intervention in a fully powered, larger, method-
ically rigorous, multisite randomised controlled trial.
Aims
We aim to test the clinical efficacy of SlowMo over
24 weeks compared to TAU to determine the mecha-
nisms through which it reduces paranoia, and to identify
participant characteristics that moderate its effectiveness
(either by moderating the degree of change in the mech-
anism, or by influencing adherence to the intervention).
We will test the hypothesis that changes in fast thinking
mediate changes in our primary outcome of paranoia se-
verity. Consistent with our interventionist causal ap-
proach, we do not hypothesise that worry is a mediator,
as it is not targeted in the SlowMo intervention, even
though changes in worry did mediate changes in para-
noia in a recent trial, when it was the treatment target
[10]. However, we will examine any observed effects. In
addition, we have preliminary evidence of modifiers of
treatment effects that we will also take the opportunity
to investigate. Using a randomised controlled trial de-
sign, we have selected TAU as the comparator condition.
This is because there is a very low penetration of
evidence-based psychological treatment in the NHS, and
thus the key efficacy question to address at this stage is
whether SlowMo confers benefits over and above stand-
ard care. An important secondary goal is to evaluate
mechanisms of action; the trial hypotheses concern rea-
soning, and are best tested where the control condi-
tion is inactive with respect to the targeted
psychological processes.
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The main research questions are as follows:
1. Is SlowMo efficacious in reducing paranoia severity
over 24 weeks, when added to TAU, in comparison
to TAU alone?
2. Does SlowMo reduce paranoia severity by improving
fast thinking (reducing belief inflexibility and
jumping to conclusions)?
3. Do participant characteristics (i.e. their cognitive
capacities, specifically working memory and thinking
habits; and their symptoms, specifically negative
symptoms) moderate the effects of the intervention?
4. Does outcome differ by adherence to the
intervention and is adherence predicted by the
participants’ beliefs about their illness and about the
intervention?
5. Does the SlowMo digital therapy platform have
acceptable rates of usability, acceptability and
adherence?
6. Does SlowMo lead to changes in the following
secondary outcomes: other delusional symptoms,
wellbeing, quality of life, self and others schemas,
service use and worry
Hypotheses
Primary hypotheses:
1. The intervention will reduce paranoia severity over
24 weeks
2. Fast thinking (belief inflexibility and jumping to
conclusions) will improve in response to the
intervention
3. Reductions in fast thinking will mediate positive
change in paranoia severity
Secondary hypotheses:
4. Poorer working memory and more severe negative
symptoms will negatively moderate treatment effects
5. Therapy adherence will moderate the effects of
treatment on outcome and adherence will be
predicted by beliefs about mental health problems




The study design is a parallel-group randomised
controlled trial, with 1:1 allocation. Participants with
distressing persecutory beliefs who meet the inclusion
criteria (see below) will be independently randomised to
receive either the SlowMo intervention added to TAU,
or TAU. Independent randomisation (centrally adminis-
tered independently of the trial team by the King’s
Clinical Trials Unit (CTU)) will use an online system
generating randomly varying permuted blocks, stratified
by site and baseline paranoia severity. Stratification by
paranoia severity will use a median split of ≥ 62 (Green
Paranoid Thoughts Scale (GPTS) part B [36] based on
data from [10]). Research workers will be blind to ther-
apy allocation, to facilitate completion of unbiased and
objective assessments. Adherence to the blindness pro-
cedure will be supported by the research coordinator
and therapists having responsibility for the randomisa-
tion process and informing participants of randomisa-
tion outcome. Further, the blinding procedure will be
explained to participants and they will be reminded not
to inform research workers of therapy allocation. Breaks
in blinding will be monitored and recorded. Embedded
within the design will be measures to elucidate how the
treatment works. For reporting the trial, the CONSORT
(Consolidated Standards of Reporting Trials; http://
www.consort-statement.org/) Statement will be followed,
with consideration of the mHealth evidence reporting
and assessment (mERA) [37] and CONSORT-EHEALTH
Checklists [38]. For the protocol, the SPIRIT (Standard
Protocol Items: Recommendations for Interventional
Trials [39]) Checklist and Figure are provided in this
paper see: Additional file 1.
Participants
The inclusion criteria are as follows: aged 18 years and
over; persistent (3 +months) distressing paranoia (as
assessed using the Schedules for Clinical Assessment in
Neuropsychiatry (SCAN, [40]) and scoring > 29 on the
GPTS, part B, persecutory subscale [36]; diagnosis of
schizophrenia-spectrum psychosis (F20-29, ICD-10
[41]); capacity to provide informed consent; sufficient
grasp of English to participate in informed consent
process, assessments and interventions.
Criteria for exclusion are as follows: profound visual
and/or hearing impairment; inability to engage in the
assessment procedure; currently in receipt of other psy-
chological therapy for paranoia; primary diagnosis of
substance abuse disorder, personality disorder, organic
syndrome or learning disability.
Mobile ownership is not a criterion for participation,
as android smartphones with the SlowMo mobile app
will be provided.
Participants will be recruited from mental health
services across three main trial sites in England with the
same procedures followed at each site: South London
and Maudsley NHS Foundation Trust, Sussex Partner-
ship NHS Foundation Trust and Oxford Health NHS
Foundation Trust. Up to six additional Patient Identi-
fication Centres, comprising NHS trusts geographic-
ally near to the main recruitment trust sites, will be
used as required.
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Trial flowchart
Figure 1 illustrates the trial/recruitment flowchart.
Planned trial interventions
SlowMo therapy consists of eight individual, face-to-face
sessions, of 60–90 min, delivered by trained therapists
within a 12-week timeframe, assisted by a web-based
app hosted on a touchscreen laptop, with interactive
personal accounts and tasks. Initial sessions involve
building the meta-cognitive skill of noticing thoughts
and thinking habits (visualised as bubbles spinning faster
or more slowly). People learn that everyone thinks fast
at times, and this can be useful. However, thinking
slowly can be helpful in dealing with stress and fears
about other people. This key principle frames the ses-
sions in which people are supported to try out tips to
slow down for a moment, e.g. by considering the impact
of mood and past experiences on concerns and by look-
ing for safer alternative explanations. There is an em-
phasis throughout the intervention on practising the
skills inside and outside sessions. Participants build con-
fidence in managing paranoia, feeling safer in their daily
life and working towards a valued goal. The overall
session structure is fixed, but individual content is per-
sonalised throughout as participants record their indi-
vidual worries, ways of feeling safer, key learning from
each session, and a message for the week ahead. All of
the personalised session content is synchronised with a
native mobile app installed on a standard android smart-
phone to assist therapy generalisation into daily life. This
allows people to notice their fears and thinking habits,
and supports them to slow down for a moment, by pro-
viding strategies, encouraging them to audio- or text-
record helpful new information and to generate safer
thoughts. Recorded information is stored in a format
whereby, when experiencing recurrent concerns, people
can readily access what was previously useful. Optional
notifications are available if people wish the app to
check-in with them. The app is specifically designed for
offline use, to minimise concerns about privacy and se-
curity. Participants are not given standardised instruc-
tions about when to use the app, rather the emphasis is
on tailoring usage according to what is most helpful for
the individual. Use of the app is monitored objectively
through data input and system analytics. Please see Fig. 2
for an overview of the main SlowMo screens.
Referral identified & screened
Client agrees to meet                                                           
Assess eligibility and capacity to consent, complete 
informed consent
Client does not agree to meet
RefusalClient consents Consent not given
Baseline assessments completed
Randomisation
Randomised to intervention group 
(SlowMo + TAU) (n = 180)
Intervention group follow-
up assessment at 12 weeks 
after randomisation
Intervention group follow-
up assessment at 24 weeks 
after randomisation
Randomised to control group 
(TAU) (n = 180) 
Receive 8 session SlowMo 
intervention
Control group follow-up 
assessment at 12 weeks 
after randomisation
Control group follow-up 
assessment at 24 weeks 
after randomisation
Fig. 1 SlowMo trial design and recruitment flowchart
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The development work has been done by Evolyst
Ltd., a user-centred and evidence-based health care
software development company. The design and de-
velopment of the app has been informed by the Brit-
ish Standards Institute quality criteria and code of
practice for health care apps (BSI; [42]). SlowMo uses
a proprietary software platform developed using an
Azure-based WCF (Windows Communication Foun-
dation) Web Service, acting as an Application Pro-
gramming Interface (API) to a Model View Controller
(MVC) Asp.Net Web application; and a Xamarin.An-
droid-based mobile application, allowing for use of
the full Microsoft Stack and negating interoperability
issues. SlowMo has currently been developed as a
standalone product, given the lack of consensus on
operating systems across the NHS trusts, and current
interoperability issues.
TAU is care delivered to both randomised groups,
according to national and local service protocols and
best practice guidelines (specifically, NICE guidance
on community mental health treatment for people
with psychosis and the standards of community care
required by the national regulators). Participation will
not alter usual treatment decisions about medication
and additional psychosocial interventions which
remain the responsibility of the clinical team. A
modified version of the Client Service Receipt Inven-
tory [43] will be used to measure service use. Anti-
psychotic medication data will be extracted from




Participants will complete a range of self-report and
interview-based measures to assess the impact of the
interventions on primary and secondary outcomes, the
hypothesised mediators, and other key processes impli-
cated in paranoia and response to therapy. Assessments
will be completed at baseline, 12 and 24 weeks. Every
effort will be made to ensure that data collection and
completeness is optimised throughout the trial, and to
minimise attrition/loss to follow-up. Please refer to Fig. 3
(SPIRIT Figure) for details of assessment at each visit.
Assessments will be audio-taped (after first establishing
consent) to allow evaluation of adherence to the
research protocol and assessment ratings.
The primary outcome is paranoia severity measured
by the GPTS [36] over 24 weeks. The GPTS comprises
two scales assessing thinking relevant to paranoia: ideas
of social reference and persecution, rated over the pre-
ceding month. Each item is scored on a five-point Likert
scale from 1 (‘not at all’) to 5 (‘totally’). A total score can
be calculated ranging from 32 to 160, with higher scores
reflecting higher levels of paranoia. Two 16-item
subscales assess ideas of social reference (part A) and
persecution (part B) relevant to paranoia.
Other paranoia outcomes:
Fig. 2 An overview of the SlowMo user interface (left: in-session digital platform; right: SlowMo app)
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Fig. 3 Standard Protocol Items: Recommendations for Interventional Trial (SPIRIT) Figure. A digital therapy for people who fear harm from others
(SlowMo): schedule of enrolment, interventions and assessments
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1. The Psychotic Symptom Rating Scales-Delusions
(PSYRATS-Delusions; [44]), consisting of six items
which assess the following dimensions of delusions:
amount of preoccupation with delusions, duration of
preoccupation with delusions, conviction, amount of
distress, intensity of distress and disruption to life
caused by beliefs
2. The persecutory delusions and ideas of reference
items from the Scales for Assessment of Positive
Symptoms (SAPS; [45]), a semi-structured interview
designed to assess the positive symptoms of psychosis
Hypothesised mediators are measured by changes in
fast thinking assessed by:
1. Possibility of Being Mistaken (taken from the
Maudsley Assessment of Delusions Schedule
(MADS; [46]); Alternative Explanations from the
Explanations of Experiences interview [47]). These
are commonly used published methods of assessing
lack of belief flexibility relating to delusional beliefs
2. Jumping to Conclusions (JTC) Beads Data-gathering
Task [48] versions 85:15 and 60:40.
Please refer to Fig. 3 for details of secondary outcomes
and other key processes hypothesised as moderators;
these include published and established measures of
wellbeing [49], quality of life [50], self and other schemas
[51], service use [43], worry [52], cognitive tests [45, 53–55],
other paranoia measures [56] and measures of beliefs
about mental health problems and perceived relationship
with carers [57, 58].
Safety and adverse event assessment and monitoring and
stopping rules
The occurrence of adverse events (AEs) will be moni-
tored actively and systematically, following SPIRIT guid-
ance for reporting of harms. AEs include: deaths; self-
harm; serious violent incidents; complaints about ther-
apy; and referrals to crisis care or admission to psychi-
atric hospital during therapy. A standard method of
reporting will be employed, categorising events by sever-
ity (five grades, A–E). Subject to the approval by the in-
dependent chairperson of the Data Monitoring and
Ethics Committee (DMEC, see below, ‘Research govern-
ance’), investigators will also determine whether an event
is temporally related to the intervention, and whether it
is unexpected or unexplained given the participant’s clin-
ical course, previous conditions and history, and con-
comitant treatments. Following [59], the event will then
be rated within five categories from ‘not related’ to ‘re-
lated’. Any associations between AEs and the SlowMo
hardware or software will also be recorded. At each
meeting of the DMEC, or at any time at the request of
the DMEC chairperson, a full report of AEs will be
reviewed. The DMEC will be responsible for investigat-
ing further, if there are concerns about unexpectedly
high rates of AEs. This may involve the DMEC members
being unblinded to the trial condition or seeking further
data on AEs. If there are any ethical or safety reasons
why the trial should be prematurely ended, they will ad-
vise the Trial Steering Committee (TSC) accordingly.
Individual participants will have the right to withdraw
from the trial at any time. In addition the therapist, in
collaboration with the participant and relevant clinical
team, may decide to stop the therapy if it is directly as-
sociated with a worsening of mental state. Reasons for
withdrawal from the study will be recorded. For the final
reports of the trial, the numbers, types and severity of
AEs by trial condition, as well as discontinuations, will
be reported, using descriptive statistics (since there are
no pre-specified hypotheses concerning AEs or harms,
and, given the expected low frequency of AEs, the data
will not be suitable for an intention-to-treat (ITT) statis-
tical analysis).
The trial may be prematurely discontinued by the
sponsor or chief investigator on the basis of new safety
information or for other reasons given by the DMEC,
the TSC, the regulatory authority or the Ethics Commit-
tee concerned. The trial may also be prematurely discon-
tinued due to lack of recruitment or upon advice from
the TSC, which will advise on whether to continue or
discontinue the study and make a recommendation to
the sponsor. If the study is prematurely discontinued, ac-
tive participants will be informed and no further partici-
pant data will be collected.
Accessibility, usability and acceptability assessments
Given the novelty of the digital therapy platform, its ac-
cessibility, usability and acceptability will be assessed in
the SlowMo arm. This will be done through assessment
of current mobile use and confidence at the beginning of
therapy, monitoring of connectivity for the web app, sys-
tem analytics data on the use of the platform, the User
Experience Survey (adapted from [35]), and a service-
user led qualitative interview with a sub-sample of those
receiving SlowMo (n = 20).
Therapy adherence assessments
In the SlowMo arm, therapy adherence will be assessed
from the number and duration of sessions attended, and
system analytics data on mobile app use. Therapy deliv-
ery will be evaluated in terms of fidelity to the treatment
manual.
Data management and security
All data will be anonymised at source. All personal data
will be kept in a locked filing cabinet in a locked office
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and will be kept separate from all the research data.
Therapy files will be kept in a secure office in the clinic
and will not be accessible to the staff collecting the re-
search outcome data. Data will be entered on a compu-
terised database, held centrally and managed by King’s
College London CTU, by research assistants using a se-
cure network connection. Audio-recording equipment
will be used to record assessments to check fidelity to
assessment protocols and to ensure interrater reliability.
The therapy sessions will be audio-recorded (with par-
ticipant consent) for monitoring the intervention in
terms of fidelity and competence. These audio files,
named with a unique participant identifier, will be stored
as computer files on secure NHS/university servers.
Security and privacy of information stored on the app
has been considered throughout its development. If in-
formed consent is provided, app data will only be
synched during therapy sessions, over secure connec-
tions and stored on a password-protected, secure data-
base. Data transferred will only contain a name (chosen
by the person) and a Unique Device Identifier (UDID)
which is generated automatically by the therapy plat-
form, and will match the anonymised participant num-
ber. Participants can also opt to use the app in a fully
offline mode. Participants will have the opportunity, if
they wish, to password protect the handset with a pin
number or password. During the informed consent
process potential participants will be made fully aware of
the data collected by the platform, and how data will be
stored and used. Access to this privacy and security in-
formation is also available from the settings menu of the
app, which consenting participants can access at any
time.
Data quality
Data quality will be ensured by close monitoring and
routine auditing for accuracy throughout the data collec-
tion period. In order to ensure the accuracy of the data
entered into the database, the main outcome measure
entry will be checked for every participant by comparing
the paper record with that on the database. An error
rate of no more than 5% is acceptable. This will be done
once all possible assessments for each time point have
been completed. If the error rate is higher than 5%, ad-
vice will be sought from the trial statistician and meth-
odologist regarding further data checking.
Sample size
Recruitment of 360 participants will be split equally
across sites. We have powered the study conservatively
to detect a clinically meaningful 10-point reduction in
the primary outcome measure (GTPS [36]); based on a
standard deviation of 25, this is a 0.4 effect size [10]. We
account for: clustering in the SlowMo arm with an
intraclass correlation coefficient (ICC) = 0.01 with 10
therapists (no clustering in the TAU arm), 1:1 allocation,
0.05 significance level. Calculations used Clsampsi in
Stata. A simple two-tailed t test with 150 people per
group gives 90% power to detect an effect size of 0.4,
and 80% for 0.35. In practice, power will be increased by
using multiple regression. To allow for conservatively
high 20% attrition we will recruit 360 patients at baseline
split equally across three sites (120 per site, 60 per arm
per site). For the mediational analyses, a sample of N =
300 has > 80% power to detect a proportion mediated of
40%, and > 70% power to detect a proportion mediated
of 30%, corresponding to findings in our pilot work [12]
(calculated using PowerMediation in R).
Statistical analysis
We will report all participant flow, and analyses will be
conducted on the ITT population: all participants will
be randomised regardless of non-compliance with proto-
col or withdrawal from the study. Analyses will post-
date final follow-up assessments, with due consideration
of potential biases from loss to follow-up. The primary
analysis will test for a treatment effect on the primary
and secondary clinical outcomes. Random effects regres-
sion models allowing for clustering by both participants
and therapists will be fitted to the repeated measures,
controlling for treatment site, baseline paranoia severity
and the corresponding baseline assessment for the out-
come under investigation. We will allow for missing out-
come data under the Missing At Random assumption
[60]; we may also use inverse probability weighting to
adjust for non-adherence to allocated treatment and
other intermediate outcomes as predictors of future loss
to follow-up [61]. Secondary analyses will test
treatment-effect mechanisms, moderation and process/
adherence effects using modern causal inference
methods [62, 63]. The trial outcomes will comprise two
parallel series of longitudinal data: one for the putative
mediators (M) and one for the clinical outcomes (Y).
For the mechanistic analysis, to test for a treatment
effect on the putative mediator, we will replace the clin-
ical outcome with the mechanistic variable as the
dependent variable in the random-effect models. If we
separately demonstrate a treatment effect on both the
putative mediator and on the clinical outcome, we will
evaluate mediation in these parallel longitudinal data
sets through the use of parallel growth curve and latent
change models [64, 65]. These models preserve the basic
mediation model by replacing observed variables with la-
tent constructs – the growth factors driving the tem-
poral responses, M1 to Mp and Y1 to Yp. Importantly,
the mediational structure only applies to the slope
growth or change factors since randomised treatments
are independent of the intercept growth factors (baseline
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values). Growth curve and latent change models can be
estimated by maximum likelihood and other methods
using the software package Mplus [66]. The application
of these methods to mechanism evaluation within EME
(Efficacy and Mechanism Evaluation) trials is illustrated
in [62]
The aim of these analyses is to demonstrate that the
effect of treatment on the growth (change) in the clinical
outcome (Y) is explained (caused) by its effect on the
growth (change) in the mediator. The major challenge to
a valid inference is that there may be confounding of the
mediator and outcome. We will begin by allowing for
baseline values of the mediator and of the clinical out-
come, as in the analyses of the successful EME Worry
Intervention Trial [10]. We will then check the sensitiv-
ity of the results to the possibility of hidden confounding
(unmeasured variables) through the use of instrumental
variable methods [62, 63].
Research governance and patient and public involvement
(PPI)
King’s College London is the research sponsor and the
South London and Maudsley NHS Foundations Trust is
co-sponsor. The trial has received a favourable ethical
opinion from Camberwell St. Giles Research Ethics
Committee (REC) (REC Reference: 16/LO/1862; IRAS:
206680). Any changes to the study protocol will be sub-
mitted to the REC and then communicated to all rele-
vant parties (including the DMEC, TSC and study
funders). The trial will be conducted in compliance with
the principles of the Declaration of Helsinki [67], the
Medical Research Council Guidelines for Good Clinical
Practice [68] and in accordance with all applicable regu-
latory requirements including but not limited to the Re-
search Governance Framework and the Mental Capacity
Act 2005 [69]. The chief investigator (CI) will have over-
all responsibility for the trial data set and will permit
trial-related monitoring, audits and REC review by pro-
viding the sponsor(s), and REC direct access to source
data and other documents as required. A dedicated trial
coordinator post will assist in the day-to-day manage-
ment of the project reporting to the CI. A Trial Manage-
ment Committee (TMC) will meet monthly: its
membership will include the investigators and the trial
coordinator and site coordinators. It will be chaired by
the CI and will manage the day-to-day running of the
study and oversee the preparation of reports to the TSC
and DMEC. The TSC will meet at least annually and will
include in its membership a lay member and access to
consultation with a patient and public involvement (PPI)
advisory group. The TSC’s purpose is to provide inde-
pendent overall supervision of the trial, approving the
protocol and amendments, and monitoring progress,
through audits of recruitment and data completion rates
and adherence to the protocol. It will provide independ-
ent advice on all aspects of the trial. A DMEC will be
convened and will meet at least annually and report to
the TSC. It will have access to all trial data and will re-
ceive regular reports on AEs. Membership of the DMEC
will be fully independent of the trial team and will com-
prise two independent clinician researchers, one of
whom will act as chair, and a statistician who will be in-
dependent of the applicants and of the TSC. The DMEC
chair will be notified of any serious AEs as they occur,
and with the DMEC will consider whether any interim
analyses are warranted, review data and advise the TSC
on any ethical or safety reasons why the trial should be
prematurely ended. The PPI Advisory Group will advise
on and contribute to recruitment, qualitative data collec-
tion and dissemination activities throughout the trial.
Discussion
SlowMo has been developed as the first blended digital
therapy to target fears of harm from others through an
inclusive design approach. Improving the effectiveness
and accessibility of psychological treatments for paranoia
is a clinical health priority [6]. The current trial aims to
achieve this in two ways. Firstly, adopting an interven-
tionist causal treatment approach, SlowMo therapy
tackles fast thinking, which research has shown to play a
key role in the development and maintenance of distres-
sing paranoia. Secondly, incorporating digital technolo-
gies into psychological interventions presents unique
opportunities for developing effective and accessible
treatments. However, the adoption of digital technology
cannot of itself guarantee effective therapy. We therefore
used an inclusive design approach in the development of
SlowMo therapy, with stakeholder involvement at each
stage and a clear focus on addressing the needs of the
broadest possible range of users, including sampling of
‘extreme’ users [33].
Given the strong evidence for targeting reasoning as a
treatment for paranoia [13, 70], our encouraging pilot
data, and its inclusive user-centred design, SlowMo is
expected to be highly acceptable and to lead to clinically
worthwhile improvements in paranoia severity, working
by supporting people to ‘slow down for a moment’ and
reduce their reliance on fast thinking. The data from this
study will also add significantly to our understanding of
psychological mechanisms and change processes in para-
noia. As well as providing valuable information for treat-
ment development, evidence of mechanisms of action
will inform the theoretical understanding of paranoia in
a way that may itself shape future therapeutic initiatives.
The trial will provide data on whether characteristics of
participants (including working memory and negative
symptoms) moderate the effects of the intervention on
fast thinking, and also the effect on outcome of an
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adequate dose of treatment and therapy adherence.
From the perspective of digital health, we will examine
the usability and adherence of a novel digital therapy, in-
cluding an app for self-management in daily life in a
large sample of people affected by severe mental health
difficulties. Uniquely, the mobile app allows for monitor-
ing of fast and slow thinking in real time and is, there-
fore, well placed to advance our understanding of its
role in paranoia [71].
In summary, the SlowMo trial has the potential to in-
form future stratified medicine approaches, the develop-
ment of more targeted therapies and the applicability of
digital health innovations with this population. The trial
is funded for 31 months and began in February 2017.
Final outcome assessments will be completed by sum-
mer 2019, and outcome results will become available in
2020. They will then be written up by the trial team and
published in peer-reviewed journals. Participants will re-
ceive a summary of the results, and we will also dissem-
inate findings more broadly through public engagement
activities.
Trial status
Recruitment of participants commenced in May 2017
and will be open until spring 2019. The date of first
enrolment is May 2017.
Key contacts:
Professor Philippa Garety (CI) and Dr. Thomas Ward
can be contacted for scientific queries.
Dr. Thomas Ward (trial coordinator) is the main con-
tact for general trial-related queries.
Chief investigator: Professor Philippa Garety
PO Box 77, Henry Wellcome Building, The Institute of
Psychiatry, Psychology and Neuroscience, King’s College
London, De Crespigny Park, London SE5 8AF, UK
Tel: +44 (0)20 7848 5046; Fax: +44 (0)20 7848 5006
Email: philippa.garety@kcl.ac.uk
Trial coordinator: Dr. Thomas Ward:
Psychology, PO77, HWB, King’s College London, Insti-
tute of Psychiatry, Psychology and Neuroscience, De
Crespigny Park, London SE5 8AF, UK
Tel: +44 (0) 207 848 0594; Fax: +44 (0) 207 848 5006
Email: thomas.ward@kcl.ac.uk
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Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 122 kb)
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